Cancer care is heading into its most disruptive decade. Demand is rising, the oncology workforce can’t keep pace and reimbursement pressure continues to build.
At the same time, the therapies reshaping the field are outrunning the systems meant to deliver them. Fewer than 2 in 10 eligible patients access chimeric antigen receptor T-cell, or CAR-T, therapy today, despite a clear FDA pathway. The next wave is already in motion for first approvals by 2030, including autoimmune applications, in vivo engineering and off-the-shelf cell therapies. Health systems that wait to build readiness risk negotiating from behind.
In this webinar, Douglas B. Flora, MD, of Edgewood, Ky.-based St. Elizabeth Healthcare, will join Kelley D. Simpson, managing director and oncology services leader. Dr. Flora is executive medical director of oncology services at the system’s Yung Family Cancer Center and president-elect of the Association of Cancer Care Centers. Together, they will outline what boards need to see now and what separates the systems that turn access into outcomes.
Learnings include:
- Why readiness, not regulation, is limiting CAR-T access, and what systems that convert access into outcomes do differently
- How CAR-T’s move into community and outpatient settings, along with autoimmune and in vivo therapies, will change what cancer programs must be prepared to deliver
- What a new multisystem cancer collaborative will tackle first across workforce, reimbursement and site of care, and how health systems can get involved early